319 related articles for article (PubMed ID: 31511361)
21. Functional crosstalk between angiotensin receptors (types 1 and 2) and relaxin family peptide receptor 1 (RXFP1): Implications for the therapeutic targeting of fibrosis.
Samuel CS; Li Y; Wang Y; Widdop RE
Br J Pharmacol; 2024 Jul; 181(14):2302-2318. PubMed ID: 36560925
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous inflammation differentially regulates the expression and function of Angiotensin-II types 1 and 2 receptors in rat primary sensory neurons.
Benitez SG; Seltzer AM; Messina DN; Foscolo MR; Patterson SI; Acosta CG
J Neurochem; 2020 Mar; 152(6):675-696. PubMed ID: 31386177
[TBL] [Abstract][Full Text] [Related]
23. Role of Mas receptor antagonist (A779) on pressure diuresis and natriuresis and renal blood flow in the absence of angiotensin II receptors type 1 and 2 in female and male rats.
Mansoori A; Oryan S; Nematbakhsh M
J Physiol Pharmacol; 2014 Oct; 65(5):633-9. PubMed ID: 25371522
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control.
Mitsuishi M; Miyashita K; Muraki A; Itoh H
Diabetes; 2009 Mar; 58(3):710-7. PubMed ID: 19074984
[TBL] [Abstract][Full Text] [Related]
25. AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction.
Jugdutt BI; Menon V
Mol Cell Biochem; 2004 May; 260(1-2):111-8. PubMed ID: 15228092
[TBL] [Abstract][Full Text] [Related]
26. Reduced sensitivity of the renal vasculature to angiotensin II in young rats: the role of the angiotensin type 2 receptor.
Brown RD; Hilliard LM; Mirabito KM; Wirth LC; Moritz KM; Evans RG; Denton KM
Pediatr Res; 2014 Nov; 76(5):448-52. PubMed ID: 25119338
[TBL] [Abstract][Full Text] [Related]
27. Altered expression of RXFP1 receptor contributes to the inefficacy of relaxin-based anti-fibrotic treatments in systemic sclerosis.
Corallo C; Pinto AM; Renieri A; Cheleschi S; Fioravanti A; Cutolo M; Soldano S; Nuti R; Giordano N
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):69-75. PubMed ID: 31365333
[TBL] [Abstract][Full Text] [Related]
28. Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment.
Jelinic M; Leo CH; Post Uiterweer ED; Sandow SL; Gooi JH; Wlodek ME; Conrad KP; Parkington H; Tare M; Parry LJ
FASEB J; 2014 Jan; 28(1):275-87. PubMed ID: 24036884
[TBL] [Abstract][Full Text] [Related]
29. Role of Mas receptor antagonist (A779) in renal hemodynamics in condition of blocked angiotensin II receptors in rats.
Mansoori A; Oryan S; Nematbakhsh M
Physiol Int; 2016 Mar; 103(1):13-20. PubMed ID: 27030624
[TBL] [Abstract][Full Text] [Related]
30. Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity.
Pini A; Shemesh R; Samuel CS; Bathgate RA; Zauberman A; Hermesh C; Wool A; Bani D; Rotman G
J Pharmacol Exp Ther; 2010 Dec; 335(3):589-99. PubMed ID: 20826567
[TBL] [Abstract][Full Text] [Related]
31. Increased AT(2)R protein expression but not increased apoptosis during cardioprotection induced by AT(1)R blockade.
Moudgil R; Musat-Marcu S; Xu Y; Kumar D; Jugdutt BI
Can J Cardiol; 2002 Oct; 18(10):1107-16. PubMed ID: 12420045
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists.
Cosentino F; Savoia C; De Paolis P; Francia P; Russo A; Maffei A; Venturelli V; Schiavoni M; Lembo G; Volpe M
Am J Hypertens; 2005 Apr; 18(4 Pt 1):493-9. PubMed ID: 15831358
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy.
Ma YP; Yang Y; Jiang SM; Liu L; Zhang Z; Wang YN; Zou GM; Li WG
J Renin Angiotensin Aldosterone Syst; 2020; 21(2):1470320320919607. PubMed ID: 32370637
[TBL] [Abstract][Full Text] [Related]
34. Different effects of angiotensin receptor blockade on end-organ damage in salt-dependent and salt-independent hypertension.
Maitland K; Bridges L; Davis WP; Loscalzo J; Pointer MA
Circulation; 2006 Aug; 114(9):905-11. PubMed ID: 16923758
[TBL] [Abstract][Full Text] [Related]
35. Alterations of relaxin and its receptor system components in experimental diabetic cardiomyopathy rats.
Zhang X; Pan L; Yang K; Fu Y; Liu Y; Chen W; Ma X; Yin X
Cell Tissue Res; 2017 Nov; 370(2):297-304. PubMed ID: 28776188
[TBL] [Abstract][Full Text] [Related]
36. Prolonged RXFP1 and RXFP2 signaling can be explained by poor internalization and a lack of beta-arrestin recruitment.
Callander GE; Thomas WG; Bathgate RA
Am J Physiol Cell Physiol; 2009 May; 296(5):C1058-66. PubMed ID: 19279230
[TBL] [Abstract][Full Text] [Related]
37. Serelaxin and the AT
Wang Y; Han L; Shen M; Jones ES; Spizzo I; Walton SL; Denton KM; Gaspari TA; Samuel CS; Widdop RE
ACS Pharmacol Transl Sci; 2020 Feb; 3(1):76-87. PubMed ID: 32259090
[TBL] [Abstract][Full Text] [Related]
38. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2.
Mookerjee I; Hewitson TD; Halls ML; Summers RJ; Mathai ML; Bathgate RA; Tregear GW; Samuel CS
FASEB J; 2009 Apr; 23(4):1219-29. PubMed ID: 19073841
[TBL] [Abstract][Full Text] [Related]
39. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo.
Samuel CS; Unemori EN; Mookerjee I; Bathgate RA; Layfield SL; Mak J; Tregear GW; Du XJ
Endocrinology; 2004 Sep; 145(9):4125-33. PubMed ID: 15155573
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the high affinity [
Abreu Diaz AM; Drumeva GO; Laporte P; Alonso Martinez LM; Petrenyov DR; Carrier JF; DaSilva JN
Nucl Med Biol; 2021; 96-97():41-49. PubMed ID: 33798796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
